Carballo and co-workers presented data showing that SHH pathway inhibition with cyclopamine interferes with GBM cell viability and also suggested that cyclopamine inhibition of the SHH pathway prior to TMZ treatment could reduce the aggressiveness of the tumor cells by sensitizing the GSCs to TMZ [83]. Here, SHH is linked to glioblastoma.